This Overlooked Memecoin Is Showing Early Breakout Signals

We've been tracking one small memecoin that checks all the boxes: strong on-chain signals, real traction, and an entry point that could offer serious upside. It's not on many radars yet-but that could change fast.

Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On?

Evette Mitkov
November 13, 2025

Clearmind Medicine Inc (NASDAQ:CMND) shares are trading higher on Thursday. The company reported that Hadassah Medical Center in Jerusalem has given its final approval for an ongoing Phase 1/2a clinical trial, which is assessing CMND-100’s potential to treat alcohol use disorder (AUD).

  • CMND is delivering impressive returns. See what is driving the move here.

What To Know: The clinical-stage biotech company’s CMND-100 is a proprietary MEAI-based oral drug candidate. Clearmind received final approval for its ongoing Phase 1/2a clinical trial evaluating CMND-100 for the treatment of AUD.

The first cohort treatment of Clearmind’s clinical trial was successfully completed. The approval enables Hadassah Medical Center to join the company’s clinical trial.

The Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine, and Israel’s Tel Aviv Sourasky Medical Center are among the other institutions taking part in the trial. The study at Hadassah-University Medical Center will be supervised by Joseph Caraco, the director of the clinical pharmacology unit in the medical department.

The Phase 1/2a clinical trial is a multinational, multi-center investigation intended to assess the pharmacokinetic profile, safety and tolerability of CMND-100. Additionally, the study will gauge its initial success in lowering alcohol consumption and cravings in patients with alcohol use disorder.

According to the World Health Organization, AUD causes 4.7% of all deaths globally; Clearmind’s trial aims to address this issue. With the goal of providing a ground-breaking solution for those impacted by AUD and their families, the company expects to make additional steps in patient enrollment and data collection throughout its clinical site.

CMND Price Action: Clearmind shares were up 18.05%, trading at approximately 37 cents at the time of publication on Thursday, according to Benzinga Pro. Operating in the pharmaceutical industry, Clearmind Medicine’s 52-week range shows notable volatility, peaking at $2.18, indicating a high level of investor speculation or interest in the company’s potential for growth.

Read Next:

  • Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

Image: Bigc Studio/Shutterstock.com

Continue Reading...

Popular

IRS boosts contribution limits for 401(k) retirement plan savers

Americans will be allowed to contribute more of their money to 401(k) and similar retirement saving plans next year.

AutoZone's Domestic 'Do It For Me' Business Driving Market Share Gains

Goldman Sachs upgrades AutoZone to Buy after recent sell-off, highlighting double-digit domestic DIFM growth, share gains, and long-term EPS upside through FY28.

Why Wall Street Is Piling Into the "Debasement Trade" - Ad

Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. Dr. David Eifrig's latest warning deserves your attention.

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Zohran Mamdani Says No More Thanking Veterans Today, Forgetting Tomorrow — Trump, Obama And Others Express Gratitude For Service

America's top political and tech leaders — including Donald Trump, Barack Obama, Tim Cook, and Sundar Pichai — marked Veterans Day 2025 with tributes honoring the courage and sacrifice of U.S. service members.

America's Next Security Revolution Has Begun - Ad

Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.

California revokes 17,000 driver's licenses. But the state disputes it is over immigration concerns

California plans to revoke 17,000 commercial driver’s licenses given to immigrants after the Trump administration raised concerns about people in the country illegally receiving licenses to drive a semitruck or a bus. But Gov. Gavin Newsom said that isn't the reason.

Why Airlines May Hold Pricing Power Into 2026 Even After Shutdown Disruptions

BofA Securities says US airlines are strong despite shutdown, with core demand drivers and capacity discipline supporting positive outlook.

After 50 Years of Chemo, One Biotech Could Lead the Next Cancer Breakthrough - Ad

For decades, toxic chemotherapy defined cancer care. This biotech's innovative approach could finally change that. With early results showing precision without poison, this story is one investors will want to see early.

Job Market Pessimism Among Americans Hovers At Record Highs: 'Fears of Unemployment Have Never Been This Elevated'

Job market pessimism among Americans has reached alarming levels, with a dramatic surge in fears about unemployment and job security in recent weeks.

A Low-Profile Memecoin Is Quietly Gaining Serious Momentum - Ad

While everyone's watching the big-name coins, a lesser-known memecoin is gathering speed. With unique utility, a growing user base, and strong chart signals, our research team believes this could be a breakout waiting to happen.

MSNBC's name is being replaced, but its leaders insist that its mission will remain the same

NEW YORK (AP) — Asked what viewers should expect when television's MSNBC makes its from NBC News final this weekend, network president Rebecca Kutler points to a poster on the wall of a conference room at its new offices off Times Square.

The Real Reason This Analyst Still Calls Nebius His Favorite Neocloud Player

Nebius Group (NASDAQ: NBIS) reported strong Q3 results, boosting capacity & revenue guidance through 2026. Analyst reiterated Buy rating.

Buy This Stock Tomorrow? - Ad

A renowned former hedge fund manager - friends to some of the biggest investors in the world - just released a new list of his favorite AI stocks... and not a single Magnificent 7 name made the cut. Instead, an AI stock you've likely never heard of just flagged as "near-perfect" in his new investing scoring system.

Trump administration and private investors sign off on $1.4 billion deal with rare earth startups

WASHINGTON (AP) — The Trump administration and private investors are partnering with two rare earth startups in a $1.4 billion deal to scale up the nation's access to materials and technology that is crucial for producing an array of high-tech goods and military equipment.

"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad

George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit before November 18's bombshell.

Jim Cramer: Chipotle Is 'Too Expensive,' Buy This Plane Maker

On "Mad Money," Cramer discusses Henry Schein, Bloom Energy, Tyler Technologies, Boeing and Chipotle Mexican Grill.

Time To Sell XRP? These 3 Indicators Scream 'Take Profits'

XRP (CRYPTO: XRP) fell below key moving averages on Wednesday, signaling fading bullish momentum as multiple indicators flashed a strong sell warning.

The New Gold Trade Dominating on Wall Street - Ad

Wall Street has been making headlines lately for piling into gold. According to Dr. David Eifrig, the gold bull run is just getting started. He says you should move your money to his No. 1 gold stock immediately (not a miner or ETF but it has 1,000% upside potential.)

Meta Stock Continues To Slide: What's Going On?

Meta Platforms Inc (NASDAQ:META) shares are trading lower on Wednesday. Here's everything you need to know.

The K7 Is Changing the Economics of Security - Ad

$65-an-hour guards can't compete with a $15-an-hour AI machine that never sleeps. The K7 delivers nonstop protection and smarter analytics that improve with every patrol.

FAA says flight cuts will stay at 6% because more air traffic controllers are coming to work

WASHINGTON (AP) — Flight reductions at 40 major U.S. airports will remain at 6% instead of rising to 10% by the end of the week because more air traffic controllers are coming to work, the Department of Transportation and the Federal Aviation Administration announced Wednesday.

Traders Love This Time Of Year For Broadcom — Here's Why It Rarely Fails

Broadcom stock has gained in 14 of the last 16 mid-November to mid-December periods, with an average return of 8.9%.

Another Gold High? Here's the Move Wall Street Is Missing ... - Ad

Gold just surged past $4,200, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.

FDA says drugmakers have recalled a blood pressure medicine tainted with a cancer-causing chemical

The U.S. Food and Drug Administration says drugmakers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-causing chemical.

A medley of tech gifts for everyone on your holiday shopping list

NEW YORK (AP) — It's the most wonderful time of the year, unless you want to find the perfect gifts for .

This Overlooked Memecoin Is Showing Early Breakout Signals - Ad

We've been tracking one small memecoin that checks all the boxes: strong on-chain signals, real traction, and an entry point that could offer serious upside. It's not on many radars yet-but that could change fast.

Court Blocks Trump's SNAP Reductions, But Stricter Eligibility Rules Begin

New work requirements for SNAP begin Saturday, but benefits may not be issued through November due to the government shutdown.

Cathie Wood Goes Big On Alibaba With $25 Million Share Purchase, Scales Back On This Social Media Stock

Ark Invest made big moves in its portfolio, focusing on Alibaba, Baidu, and Reddit amid evolving market dynamics and regulatory challenges.

Why Wall Street Is Piling Into the "Debasement Trade" - Ad

Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. Dr. David Eifrig's latest warning deserves your attention.

Meta, Alphabet, Chipotle, Microsoft And Starbucks: Why These 5 Stocks Are On Investors' Radars Today

Major stock indexes traded mixed on Wednesday, with the Dow Jones Industrial Average slipping nearly 0.2% to 47,632 and the S&P 500 holding steady at 6,890.59.

Nearly 8 Million Shiba Inu Vanish After First SHIB ETF Filing Shakes Market

Nearly 8 million Shiba Inu (CRYPTO: SHIB) tokens have been incinerated following the inaugural filing of a Shiba Inu ETF, rekindling interest in the popular meme token.

America's Next Security Revolution Has Begun - Ad

Built for endurance, powered by AI, and proven in the field, the K7 is redefining protection for ports, energy hubs, and cities across the nation. The rollout is already underway.

Nvidia Packaging Partner Amkor Logs Momentum Gain— Up Over 30% YTD On AI Surge

Amkor Technologies (AMKR) hits top momentum percentile, up over 30% YTD as Nvidia's key CoWoS/HBM partner. AI surge drives gains.

After 50 Years of Chemo, One Biotech Could Lead the Next Cancer Breakthrough - Ad

For decades, toxic chemotherapy defined cancer care. This biotech's innovative approach could finally change that. With early results showing precision without poison, this story is one investors will want to see early.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service